Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Non-Current Liabilities: 2021-2024

Historic Other Non-Current Liabilities for Relay Therapeutics (RLAY) over the last 3 years, with Mar 2024 value amounting to $11.4 million.

  • Relay Therapeutics' Other Non-Current Liabilities fell 63.75% to $11.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $11.4 million, marking a year-over-year decrease of 63.75%. This contributed to the annual value of $13.2 million for FY2023, which is 59.21% down from last year.
  • Latest data reveals that Relay Therapeutics reported Other Non-Current Liabilities of $11.4 million as of Q1 2024, which was down 13.87% from $13.2 million recorded in Q4 2023.
  • In the past 5 years, Relay Therapeutics' Other Non-Current Liabilities ranged from a high of $50.5 million in Q3 2021 and a low of $11.4 million during Q1 2024.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $31.4 million (2023), whereas its average is $31.1 million.
  • Data for Relay Therapeutics' Other Non-Current Liabilities shows a maximum YoY crashed of 63.75% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Relay Therapeutics' Other Non-Current Liabilities stood at $50.3 million in 2021, then plummeted by 35.58% to $32.4 million in 2022, then plummeted by 59.21% to $13.2 million in 2023, then crashed by 63.75% to $11.4 million in 2024.
  • Its Other Non-Current Liabilities stands at $11.4 million for Q1 2024, versus $13.2 million for Q4 2023 and $28.0 million for Q3 2023.